This is a working overview of thymosin beta-4, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-03. Anything still debated is marked as such rather than presented as settled.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilised cake or powder |
| Solubility class | Freely soluble in water | Aqueous buffers also used |
| Typical storage temperature | About -20 degrees Celsius | Dry, sealed and protected from light |
| Typical analytical method | Reversed-phase HPLC or LC-MS/MS | Used for purity, identity and quantification |
| Common synonyms | Thymosin beta-4 fragment | Also listed under fragment-based descriptions |
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
Further action is planned for Saturday, the day of the FA Cup Final, and on Friday by members of RMT. A huge wildfire covering 30 mi2 (78 km2), possibly the largest ever seen in the UK, is brought under control by the Scottish Fire and Rescue Service at Cannich in the Highlands.
=== Separation and quantitation === The amino acids can be separated by ion-exchange chromatography then derivatized to facilitate their detection. More commonly, the amino acids are derivatized then resolved by reversed phase HPLC. An example of the ion-exchange chromatography is given by the NTRC using sulfonated polystyrene as a matrix, adding the amino acids in acid solution and passing a buffer of steadily increasing pH through the column. Amino acids are eluted when the pH reaches their respective isoelectric points. Once the amino acids have been separated, their respective quantities are determined by adding a reagent that will form a coloured derivative. If the amounts of amino acids are in excess of 10 nmol, ninhydrin can be used for this; it gives a yellow colour when reacted with proline, and a vivid purple with other amino acids. The concentration of amino acid is proportional to the absorbance of the resulting solution. With very small quantities, down to 10 pmol, fluorescent derivatives can be formed using reagents such as ortho-phthaldehyde (OPA) or fluorescamine. Pre-column derivatization may use the Edman reagent to produce a derivative that is detected by UV light. Greater sensitivity is achieved using a reagent that generates a fluorescent derivative. The derivatized amino acids are subjected to reversed phase chromatography, typically using a C8 or C18 silica column and an optimised elution gradient.
Plasmin is an important enzyme (EC 3.4.21.7) present in blood that degrades many blood plasma proteins, including fibrin clots. The degradation of fibrin is termed fibrinolysis. In humans, the plasmin protein (in the zymogen form of plasminogen) is encoded by the PLG gene.
== Accords == On February 19, 2015, representatives from the Malian government and the Coordination of Azawad Movements (CMA) agreed upon a new document, including the cessation of hostilities, as negotiations to end the broader war continued in Algiers. On March 1, a mediation agreement was proposed by Algeria, which was accepted by Mali and pro-government militias. The CMA asked for some time to consider the agreement, as there were no propositions for autonomy or federalism for northern Mali, which angered a large portion of Tuareg rebels. The CMA announced their refusal to sign the agreement on April 10. On April 27, the pro-government GATIA and Arab Movement of Azawad (MAA) captured Menaka, initiating new clashes between Tuareg rebels and the pro-government militias. On May 10, the CMA initialized the agreement, but did not sign the text. The peace agreement was signed on May 15 in Bamako by the Malian government, representatives of pro-government militias, and representatives from Algeria, Burkina Faso, Mauritania, Niger, Nigeria, Chad, the African Union, the United Nations, ECOWAS, the Organisation of Islamic Cooperation, the European Union, and France. No CMA representatives were present for the signing on May 15. That same day, fighting broke out near Menaka. Under pressure from international organizations, the CMA finally signed the agreement in Bamako on June 20. The CMA's representative was Sidi Brahim Ould Sidati, a leader of the MAA.
Sources: en.wikipedia.org
Pazopanib, sold under the brand name Votrient, is an anti-cancer medication marketed worldwide by Novartis. It is a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis. It has been approved for renal cell carcinoma and soft tissue sarcoma by numerous regulatory administrations worldwide.
April 25 Trump is evacuated after a shooting occurs at the White House Correspondents' Dinner. One law enforcement officer is struck in a bullet-resistant vest and is expected to recover. A 31-year-old male suspect is subdued and taken into custody. The US military announces that its strike on an alleged drug boat in the eastern Pacific killed two people. April 26 – 2026 NASCAR Cup Series: In NASCAR, a 26-car pileup occurs during the Jack Link's 500 at the Talladega Superspeedway after driver Bubba Wallace was pushed from outside. April 27 The suspect in the White House Correspondents' Dinner shooting is charged with attempting to assassinate the president, along with weapon offences relating to the incident at the Washington DC Hilton. He does not enter a plea. King Charles and Queen Camilla arrive in the US for a state visit. April 28 – Former FBI director James Comey is indicted on federal charges of threatening the president. The charges are related to a post he made in May 2025, which included a photo of seashells on the beach arranged to spell "86 47". April 29 The Washington Post reports that the USS Gerald R. Ford will exit the Middle East and return to Virginia in the coming days after spending 10 months at sea. Louisiana v. Callais: The Supreme Court, in a 6–3 decision, rules that Louisiana's new redistricting map was an unconstitutional racial gerrymander under the Fifteenth Amendment. April 30 Camp Mystic in Texas withdraws an application to reopen during the summer in the wake of the floods in July 2025.
Hydrogen (1H) has three naturally occurring isotopes: 1H, 2H, and 3H. 1H and 2H are stable, while 3H has a half-life of 12.32 years. Heavier isotopes also exist; all are synthetic and have a half-life of less than 1 zeptosecond (10−21 s). Hydrogen is the only element whose isotopes have different names that remain in common use today: 2H is deuterium and 3H is tritium. The symbols D and T are sometimes used for deuterium and tritium; IUPAC (International Union of Pure and Applied Chemistry) accepts said symbols, but recommends the standard isotopic symbols 2H and 3H, to avoid confusion in alphabetic sorting of chemical formulas. 1H, with no neutrons, may be called protium to disambiguate. During the early study of radioactivity, some other heavy radioisotopes were given names, but such names are rarely used today.
Sources: en.wikipedia.org
Sealed, dry and protected from light at reduced temperature is the usual laboratory convention. Allowing a cold vial to reach room temperature before opening limits condensation. Repeated opening exposes the powder to moisture and should be minimised.
Reported purity reflects the batch tested, the chromatographic method used and whether an independent laboratory performed the work. Values quoted without method detail or a traceable certificate are difficult to compare directly.
Short peptides are rapidly broken down by proteases and appear at low concentrations in urine, so the detection window is narrow. Sensitive extraction combined with tandem mass spectrometry is typically required.
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.